Unknown

Dataset Information

0

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.


ABSTRACT: We assessed the long-term results of autologous stem-cell transplantation for patients with first-relapsed or refractory Hodgkin lymphoma included in the prospective Lymphoma Study Association/Société Française de Greffe de Moelle H96 trial. This large multicenter phase II trial evaluated a risk-adapted strategy with single or tandem autologous stem-cell transplantation for 245 Hodgkin lymphoma patients. Poor-risk patients (n=150) had primary refractory Hodgkin lymphoma (n=77) or ?2 risk factors at first relapse (n=73) and were eligible for tandem autologous stem-cell transplantation. Intermediate-risk patients (n=95) had one risk factor at first relapse and were eligible for single autologous stem-cell transplantation. With a median follow-up of 10.3 years, 10-year freedom from second failure and overall survival rates were, respectively: 64% (95% CI, 54% to 74%) and 70% (95% CI, 61% to 80%) for the intermediate-risk group, and 41% (95% CI, 33% to 49%) and 47% (95% CI, 39% to 55%) for the poor-risk group. Considering only patients who did not relapse after completing autologous stem-cell transplantation, the 15-year cumulative incidences of second primary malignancies were 24% for the 70 intermediate-risk patients and 2% for the 75 poor-risk ones. With long-term follow-up, the risk-adapted strategy remains appropriate. Tandem autologous stem-cell transplantation can still be considered an option for poor-risk patients, but integration of positron-emission tomography findings and new drugs may help to refine the need for a second autologous stem-cell transplant and possibly improve outcomes of patients with first-relapsed or refractory Hodgkin lymphoma.

SUBMITTER: Sibon D 

PROVIDER: S-EPMC5004408 | biostudies-other | 2016 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

Sibon David D   Morschhauser Franck F   Resche-Rigon Matthieu M   Ghez David D   Dupuis Jehan J   Marçais Ambroise A   Deau-Fischer Bénédicte B   Bouabdallah Reda R   Sebban Catherine C   Salles Gilles G   Brice Pauline P  

Haematologica 20151231 4


We assessed the long-term results of autologous stem-cell transplantation for patients with first-relapsed or refractory Hodgkin lymphoma included in the prospective Lymphoma Study Association/Société Française de Greffe de Moelle H96 trial. This large multicenter phase II trial evaluated a risk-adapted strategy with single or tandem autologous stem-cell transplantation for 245 Hodgkin lymphoma patients. Poor-risk patients (n=150) had primary refractory Hodgkin lymphoma (n=77) or ≥2 risk factors  ...[more]

Similar Datasets

| S-EPMC5889038 | biostudies-literature
| S-EPMC7993097 | biostudies-literature
| S-EPMC7290321 | biostudies-literature
| S-EPMC8212249 | biostudies-literature
| S-EPMC7028067 | biostudies-literature
| S-EPMC6695562 | biostudies-literature
| S-EPMC5811230 | biostudies-literature
| S-EPMC3166401 | biostudies-other
| S-EPMC6075855 | biostudies-literature
| S-EPMC9578248 | biostudies-literature